Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures

Journal of NeuroInterventional Surgery

Volumn 5, Issue 4, 2013, Pages 337-343

  Hassan Akbari, S ^a   Reynolds, Matthew R ^a   Kadkhodayan, Yasha ^b   Cross III, DeWitte T ^a,b   Moran, Christopher J ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ONYX COPOLYMER; PRASUGREL; TICLOPIDINE;

ADULT; ARTERY PERFORATION; ARTICLE; BASILAR ARTERY PERFORATION; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD TRANSFUSION; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; BRAIN VENTRICLE PERITONEUM SHUNT; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; COIL EMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DURAL ARTERIOVENOUS FISTULA; ENDOVASCULAR SURGERY; EPISTAXIS; EXTRACRANIAL ARTERIAL STENOSIS; FEMALE; FLANK HEMATOMA; GASTROINTESTINAL HEMORRHAGE; GROIN HEMATOMA; HEMATOMA; HEMODYNAMICS; HUMAN; HYDROCEPHALUS; INTRACRANIAL ARTERIAL STENOSIS; INTRAPARENCHYMAL HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NECK HEMATOMA; OBSTRUCTIVE HYDROCEPHALUS; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCROTAL HEMATOMA; STENT; SUBARACHNOID HEMORRHAGE; THROMBOSIS;

ADULT; AGED; CEREBRAL HEMORRHAGE; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PIPERAZINES; PURINERGIC P2X RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; THIOPHENES;

EID: 84879393504     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2012-010334     Document Type: Article

References (25)

1. Qureshi AI, Luft AR, Sharma M, et al. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: part II - clinical aspects and recommendations. Neurosurgery 2000;46:1360-1375.
2. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-2241.
3. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
4. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:216-235.
5. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411-2420.
6. Howington JU, Hanel RA, Harrigan MR, et al. The Neuroform stent, the first microcatheter-delivered stent for use in the intracranial circulation. Neurosurgery 2004;54:2-5.
7. Qureshi AI, Luft AR, Sharma M, et al. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: part Idpathophysiological and pharmacological features. Neurosurgery 2000;46:1344-1359.
8. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting. Circulation 2003;107:2908-2913.
9. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
10. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317.
11. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of periinterventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
12. Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005;31:184-194.
13. Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine p2y12 inhibitor. Pharmacotherapy 2009;29:1089-1102.
14. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010;121:71-79.
15. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-1104.
16. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007;100:331-336.
17. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-1363.
18. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
19. Armero S, Bonello L, Berbis J, et al. Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. Am J Cardiol 2011;108:1710-1713.
20. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627-635.
21. Kalyanasundaram A, Lincoff AM. Managing adverse effects and drugedrug interactions of antiplatelet agents. Nat Rev Cardiol 2011;8:592-600.
22. Leslie-Mazwi TM, Chandra RV, Oh DC, et al. Novel use of prasugrel for intracranial stent thrombosis. J Neurointerv Surg. Published Online First: 18 February 2011. doi: 10.1136/jnis.2010.004382.
23. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-e493.
24. Lordkipanidzé M, Pharand C, Nguyen TA, et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008;29:2877-2885.
25. Bouman H, Parlak E, Van Werkum J, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemostasis 2010;8:482-488.